Drug Delivery Strategies for Antivirals against Hepatitis B Virus
AbstractChronic hepatitis B virus (HBV) infection poses a significant health challenge due to associated morbidity and mortality from cirrhosis and hepatocellular cancer that eventually results in the breakdown of liver functionality. Nanotechnology has the potential to play a pivotal role in reducing viral load levels and drug-resistant HBV through drug targeting, thus reducing the rate of evolution of the disease. Apart from tissue targeting, intracellular delivery of a wide range of drugs is necessary to exert a therapeutic action in the affected organelles. This review encompasses the strategies and techniques that have been utilized to target the HBV-infected nuclei in liver hepatocytes, with a significant look at the new insights and most recent advances in drug carriers and their role in anti-HBV therapy. View Full-Text
Share & Cite This Article
Singh, L.; Indermun, S.; Govender, M.; Kumar, P.; du Toit, L.C.; Choonara, Y.E.; Pillay, V. Drug Delivery Strategies for Antivirals against Hepatitis B Virus. Viruses 2018, 10, 267.
Singh L, Indermun S, Govender M, Kumar P, du Toit LC, Choonara YE, Pillay V. Drug Delivery Strategies for Antivirals against Hepatitis B Virus. Viruses. 2018; 10(5):267.Chicago/Turabian Style
Singh, Latavia; Indermun, Sunaina; Govender, Mershen; Kumar, Pradeep; du Toit, Lisa C.; Choonara, Yahya E.; Pillay, Viness. 2018. "Drug Delivery Strategies for Antivirals against Hepatitis B Virus." Viruses 10, no. 5: 267.
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.